Biogen says it will up Samsung Bioepis cut
Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.
Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.